Introduction: Sirtuin-2 is a histone deacetylases enzyme (HDAC), involved in inactivation about some genes, and act like a tumor gene supressor, but in many cancers, occurs alterations in this enzyme like mutations and more expression, and the enzyme inhibits another tumor suppressor genes, like a P53 gene known as the genome guardian. This enzyme is an important therapeutic target, when the inhibition of this molecule, other tumor suppressor genes are not inhibited, and like this, more contributions in cancer combat are possible. EX-527 is a potent inhibitor to Sirtuin-1 and it is a great opportunity to study the interaction of this molecule with Sirtuin-2, and propose improvements in chemistry structure in addition to developing new drugs. Objectives: Apply molecular docking techniques to study the conformational position of the molecule EX-527 complexed with sirtuin-2 investigate the molecular mechanisms of this bound and propose structural modifications and new molecules to complement the cancer treatment. Methods: Protein Data Bank was used to access the Ex-527 structure by PDB code: 4BUZ, and PDB code: 8TGP, all molecules were prepared using UCSF ChimeraX 1.10 and PyMol 3.1. The molecular docking and redocking was used with the Molegro Virtual Docker 5.5, with 1000 runs and 50 possible conformations of the EX-527 in sirtuin-2 cavity, Van der Waals interactions, electrostatic interactions and intramolecular and intermolecular interactions were analyzed. Results: The molecular docking results showed a good results by the interaction of the Ex-527 and sirtuin-2, with a -97.54 moldock score, RMSD (Root Mean Square Deviation) 0.46 and Hbond -5.54, which show a good interaction, stability and a strong interaction, showing a important binds with a key amino acids like a aspartate 170 with 2.9 angstroms distance, and isoleucine 169 with 3.09 angstroms distance. Conclusion: The cancer treatment of epigenetic alterations is important because modifications in molecules like genes and enzymes are reversible, so the inhibition of sirtuin-2 in some cancers can help the treatment of the patient, reducing the expression of oncogenes. Sirtuin-2 can inhibit tumor suppressor genes in cancer, and inhibiting this enzyme, can reduce cellular activity. The study of the interaction by enzyme and inhibitor can show how this interaction happens, like this the advance in treatment is possible. The study perspective is to test other molecular modeling techniques like molecular dynamics and in the future test in vitro and in vivo models, and from this interaction studying the enzyme cavity, propose other inhibitors. Tests in vitro were performed showing a reduction in the progression of cancer cells.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
